{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:14:00Z","timestamp":1789704840199,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1124\/dmd.118.081737","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T15:30:17Z","timestamp":1526484617000},"page":"1083-1090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals"],"prefix":"10.1016","volume":"46","author":[{"given":"Eiji","family":"Hishinuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Akai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariyasu","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.081737_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10545-005-4218-0","article-title":"Dihydropyrimidine dehydrogenase deficiency presenting at birth","volume":"28","author":"Al-Sanna\u2019a","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1124\/dmd.118.081737_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0163-7258(90)90080-L","article-title":"Metabolism of pyrimidine analogues and their nucleosides","volume":"48","author":"Daher","year":"1990","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.118.081737_bib3","doi-asserted-by":"crossref","first-page":"13155","DOI":"10.1074\/jbc.M111877200","article-title":"Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer","volume":"277","author":"Dobritzsch","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.118.081737_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/emboj\/20.4.650","article-title":"Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil","volume":"20","author":"Dobritzsch","year":"2001","journal-title":"EMBO J"},{"key":"10.1124\/dmd.118.081737_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"10.1124\/dmd.118.081737_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1124\/dmd.118.081737_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cam4.95","article-title":"Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer","volume":"2","author":"Ide","year":"2013","journal-title":"Cancer Med"},{"key":"10.1124\/dmd.118.081737_bib8","doi-asserted-by":"crossref","first-page":"e0120324","DOI":"10.1371\/journal.pone.0120324","article-title":"Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/dmd.118.081737_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12885-016-2826-8","article-title":"Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma","volume":"16","author":"Kunicka","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1124\/dmd.118.081737_bib10","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.bbapap.2010.08.014","article-title":"Insights into the mechanism of dihydropyrimidine dehydrogenase from site-directed mutagenesis targeting the active site loop and redox cofactor coordination","volume":"1804","author":"Lohkamp","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.118.081737_bib11","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","article-title":"Purification and characterization of dihydropyrimidine dehydrogenase from human liver","volume":"267","author":"Lu","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.118.081737_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s10038-007-0186-6","article-title":"Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences","volume":"52","author":"Maekawa","year":"2007","journal-title":"J Hum Genet"},{"key":"10.1124\/dmd.118.081737_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008571-200203000-00007","article-title":"A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms","volume":"12","author":"Mattison","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.118.081737_bib14","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.118.081737_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2125.2010.03686.x","article-title":"Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation","volume":"70","author":"Mounier-Boutoille","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081737_bib16","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1038\/ncomms9018","article-title":"Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals","volume":"6","author":"Nagasaki","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.118.081737_bib17","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.118.081737_bib18","doi-asserted-by":"crossref","unstructured":"Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T (2016) Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma [published correction appears in BMC Cancer (2016) 16:272]. BMC Cancer 16:156.","DOI":"10.1186\/s12885-016-2159-7"},{"key":"10.1124\/dmd.118.081737_bib19","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2001.19.18.3801","article-title":"Mortality associated with irinotecan plus bolus fluorouracil\/leucovorin: summary findings of an independent panel","volume":"19","author":"Rothenberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.118.081737_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.21037\/jgo.2016.03.02","article-title":"Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience","volume":"7","author":"Sahu","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1124\/dmd.118.081737_bib21","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.118.081737_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbapap.2004.06.009","article-title":"Dihydropyrimidine dehydrogenase: a flavoprotein with four iron-sulfur clusters","volume":"1701","author":"Schnackerz","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.118.081737_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2012.08.015","article-title":"A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy","volume":"414","author":"Sistonen","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1124\/dmd.118.081737_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cpt.210","article-title":"Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil\/uracil ratio","volume":"99","author":"Thomas","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081737_bib25","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.081737_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1124\/dmd.118.081737_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbadis.2016.12.010","article-title":"Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing","volume":"1863","author":"van Kuilenburg","year":"2017","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.118.081737_bib28","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1002\/phar.1841","article-title":"Early-Onset 5-fluorouracil toxicity in a patient negative for dihydropyrimidine dehydrogenase mutations: the clinical course of reversal with uridine triacetate","volume":"36","author":"Vaudo","year":"2016","journal-title":"Pharmacotherapy"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.081737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:37:09Z","timestamp":1739903829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624055879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0090955624055879"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.081737","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.081737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}